Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:274376.
doi: 10.1155/2010/274376. Epub 2010 Nov 1.

Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease

Bonnie L Blazer-Yost  1 , Julie Haydon, Tracy Eggleston-Gulyas, Jey-Hsin Chen, Xiaofang Wang, Vincent Gattone, Vicente E Torres
Affiliations

Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease

Bonnie L Blazer-Yost et al. PPAR Res. 2010.

Abstract

Polycystic kidney disease (PKD) is a genetic disorder characterized by growth of fluid-filled cysts predominately in kidney tubules and liver bile ducts. Currently, the clinical management of PKD is limited to cyst aspiration, surgical resection or organ transplantation. Based on an observation that PPARγ agonists such as pioglitazone and rosiglitazone decrease mRNA levels of a Cl(-) transport protein, CFTR (cystic fibrosis transmembrane conductance regulator), and the Cl(-) secretory response to vasopressin in cultured renal cells, it is hypothesized that PPARγ agonists will inhibit cyst growth. The current studies show that a 7- or 14-week pioglitazone feeding regimen inhibits renal and hepatic bile duct cyst growth in the PCK rat, a rodent model orthologous to human PKD. These studies provide proof of concept for the mechanism of action of the PPARγ agonists and suggest that this class of drugs may be effective in controlling both renal and hepatic cyst growth and fibrosis in PKD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of Pioglitazone on renal cysts in PCK rat model. The images show transverse sections of kidneys from animals that had been fed for 7 or 14 weeks with normal chow (control) or chow supplemented with pioglitazone to approximate a daily treatment of 4 or 20 mg/kg BW as indicated on the figure.
Figure 2
Figure 2
Immunostaining for CFTR in the liver of control and pioglitazone-treated PCK rats after 14 weeks of drug treatment. Control (a) or 20 mg/kg BW pioglitazone-treated (b) liver sections were immunostained for CFTR using mAb 596. Shown in both panels is the CFTR staining (brown) in the apical membranes of cyst-lining biliary epithelial cells. 1000x magnification.
Figure 3
Figure 3
Immunostaining for CFTR in the liver of control and pioglitazone-treated PCK rats after 14 weeks of drug treatment. Control (a) or 20 mg/kg BW pioglitazone-treated (b) liver sections were immunostained for CFTR with mAb 596 CFTR antibody followed by a gold-labeled secondary antibody. Shown in both panels is the CFTR staining (spherical dots) in the apical membrane sections of epithelial cells surrounding the bile duct cysts. 49 000x magnification.
See this image and copyright information in PMC

References

    1. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocrine Practice. 2003;9(5):406–416. - PubMed
    1. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Safety. 2007;30(9):741–753. - PubMed
    1. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941–2948. - PubMed
    1. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(26):9406–9411. - PMC - PubMed
    1. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nature Medicine. 2005;11(8):861–866. - PubMed

LinkOut - more resources